留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

诱导多潜能干细胞的研究进展

宋捷 缪朝玉

宋捷, 缪朝玉. 诱导多潜能干细胞的研究进展[J]. 药学实践与服务, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001
引用本文: 宋捷, 缪朝玉. 诱导多潜能干细胞的研究进展[J]. 药学实践与服务, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001
SONG Jie, MIAO Chao-yu. Progress on induced pluripotent stem cell[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001
Citation: SONG Jie, MIAO Chao-yu. Progress on induced pluripotent stem cell[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001

诱导多潜能干细胞的研究进展

doi: 10.3969/j.issn.1006-0111.2012.01.001
基金项目: 国家973计划课题(2009CB521902) ; 国家科技重大专项"重大新药创制"(2009ZX09303-002) .

Progress on induced pluripotent stem cell

  • 摘要: 诱导多潜能干细胞(IPSC)自2006年问世,就备受全球各大实验室广泛关注,成为生命科学领域新的里程碑。本篇综述旨在回顾多潜能性的研究历史,重点介绍IPSC培养技术,探讨IPSC培养技术在细胞治疗方面的应用前景。通过大量查阅国内外相关领域的综述及论著,本文归纳总结近年来IPSC领域的最新研究成果,以期为该领域后续的探索性研究提供参考。
  • [1] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors[J]. Cell, 2006, 126(4): 663.
    [2] Briggs R, King TJ. Transplantation of living nuclei from blastula cells into enucleated frogs'eggs[J]. Proc Natl Acad Sci,1952, 38(5): 455.
    [3] Miller RA, Ruddle FH. Pluripotent teratocarcinoma-thymus somatic cell hybrids[J]. Cell,1976,9(1): 45.
    [4] Xie H, Ye M, Feng R, et al. Stepwise reprogramming of B cells into macrophages[J]. Cell,2004, 117(5): 663.
    [5] Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts[J]. Cell,1987, 51(6): 987.
    [6] Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors[J]. Cell,2010, 142(3): 375.
    [7] Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes[J]. Nat Biotechnol,2008, 26(11): 1276.
    [8] Eminli S, Utikal J, Arnold K, et al. Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression[J]. Stem Cells,2008, 26(10): 2467.
    [9] Utikal J, Maherali N, Kulalert W, et al. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells[J]. J Cell Sci,2009, 122(Pt 19): 3502.
    [10] Stadtfeld M, Brennand K, Hochedlinger K. Reprogramming of pancreatic β cells into induced pluripotent stem cells[J]. Curr Biol,2008, 18(12): 890.
    [11] Sun N, Panetta NJ, Gupta DM, et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells[J]. Proc Natl Acad Sci USA, 2009,106(37):15720.
    [12] Hanna J, Markoulaki S, Schorderet P, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency[J]. Cell,2008, 133(2): 250.
    [13] Zhao XY, Li W, Lv Z, et al. iPS cells produce viable mice through tetraploid complementation[J]. Nature,2009, 461(7260): 86.
    [14] Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells[J]. Nature,2007, 448(7151): 313.
    [15] Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration[J]. Science,2008, 322(5903): 945.
    [16] Varas F, Stadtfeld M, de Andres-Aguayo L, et al. Fibroblast-derived induced pluripotent stem cells show no common retroviral vector insertions[J]. Stem Cells,2009, 27(2): 300.
    [17] Fusaki N, Ban H, Nishiyama A, et al. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome[J]. Proc Jpn Acad,2009, 85(8): 348.
    [18] Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences[J]. Science,2009, 324(5928): 797.
    [19] Jia F, Wilson KD, Sun N, et al. A nonviral minicircle vector for deriving human iPS cells[J]. Nat Methods,2010, 7(3): 197.
    [20] Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells[J]. Nature,2009, 458(7239): 766.
    [21] Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins[J]. Cell Stem Cell,2009, 4(5): 381.
    [22] Cho HJ, Lee CS, Kwon YW, et al. Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation[J]. Blood,2010, 116(3): 386.
    [23] Desponts C, Ding S. Using small molecules to improve generation of induced pluripotent stem cells from somatic cells[J]. Methods Mol Biol,2010, 636: 207.
    [24] Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells[J]. Cell,2008, 134(5): 877.
    [25] Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient[J]. Nature,2009, 457(7227): 277.
    [26] Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs[J]. Nature,2009,461(7262): 402.
    [27] Carvajal-Vergara X, Sevilla A, D'Souza SL, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome[J]. Nature,2010,465(7299): 808.
    [28] Hanna J, Wernig M, Markoulaki S, et al.Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin[J]. Science,2007, 318(5858): 1920.
    [29] M. Wernig, J. Pruszak, E. Hedlund, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease[J].Proc Natl Acad Sci,2008,105(15) : 5856.
    [30] D. Xu, LM. Fink, DM. Adcock, et al. Phenotypic correction ofmurine hemophilia A using an iPS cell-based therapy[J]. Proc Natl Acad Sci,2009,106(3) :808.
    [31] T.J. Nelson, S. Yamada, C. Perez-Terzic, et al. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells[J].Circ,2009,120(5) :408.
    [32] Raya A, Rodriguez-Piza I, Guenechea G et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells[J]. Nature,2009, 460(7251):53.
    [33] Couzin J. Celebration and concern over U.S. trial of embryonic stem cells[J]. Science,2009,323(5914):568.
  • [1] 丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉.  消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
    [2] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202306040
    [3] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
    [4] 瞿文君, 白若楠, 崔力, 周琰.  基于联合库存的公立医院多院区药品采购模式分析 . 药学实践与服务, 2024, 42(7): 1-4. doi: 10.12206/j.issn.2097-2024.202401002
    [5] 马兹芬, 许维恒, 金煜翔, 薛磊.  食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
    [6] 冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军.  雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
    [7] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 1-6. doi: 10.12206/j.issn.2097-2024.202312054
    [8] 姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量.  巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202305011
    [9] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [10] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [11] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [12] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202303023
  • 加载中
计量
  • 文章访问数:  2816
  • HTML全文浏览量:  206
  • PDF下载量:  499
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-05-06
  • 修回日期:  2011-06-08

诱导多潜能干细胞的研究进展

doi: 10.3969/j.issn.1006-0111.2012.01.001
    基金项目:  国家973计划课题(2009CB521902) ; 国家科技重大专项"重大新药创制"(2009ZX09303-002) .

摘要: 诱导多潜能干细胞(IPSC)自2006年问世,就备受全球各大实验室广泛关注,成为生命科学领域新的里程碑。本篇综述旨在回顾多潜能性的研究历史,重点介绍IPSC培养技术,探讨IPSC培养技术在细胞治疗方面的应用前景。通过大量查阅国内外相关领域的综述及论著,本文归纳总结近年来IPSC领域的最新研究成果,以期为该领域后续的探索性研究提供参考。

English Abstract

宋捷, 缪朝玉. 诱导多潜能干细胞的研究进展[J]. 药学实践与服务, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001
引用本文: 宋捷, 缪朝玉. 诱导多潜能干细胞的研究进展[J]. 药学实践与服务, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001
SONG Jie, MIAO Chao-yu. Progress on induced pluripotent stem cell[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001
Citation: SONG Jie, MIAO Chao-yu. Progress on induced pluripotent stem cell[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(1): 1-3,13. doi: 10.3969/j.issn.1006-0111.2012.01.001
参考文献 (33)

目录

    /

    返回文章
    返回